Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5193MR)

This product GTTS-WQ5193MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5193MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5106MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ15805MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9431MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ12792MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ1081MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ3370MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ8945MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14831MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW